Tipping the balance both ways: Drug resistance and virulence in Candida glabrata

FEMS Yeast Research

Volumn 15, Issue 4, 2015, Pages

  Vale Silva, Luis A ^a   Sanglard, Dominique ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antifungal drug resistance; Candida glabrata; Virulence

Indexed keywords

ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; PYRROLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; EPITHELIUM CELL; FUNGAL VIRULENCE; FUNGUS ISOLATION; HOST PATHOGEN INTERACTION; INNATE IMMUNITY; MACROPHAGE; MICROBIAL COLONIZATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SHORT SURVEY; SURVIVAL; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HUMAN; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; VIRULENCE;

ANIMALS; ANTIFUNGAL AGENTS; AZOLES; CANDIDA GLABRATA; CANDIDIASIS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; HUMANS; VIRULENCE;

EID: 84949189460     PISSN: 15671356     EISSN: 15671364     Source Type: Journal    
DOI: 10.1093/femsyr/fov025     Document Type: Short Survey

References (88)

1. Ahmad KM, Ishchuk OP, Hellborg L, et al. Small chromosomes among Danish Candida glabrata isolates originated through different mechanisms. Anton Leeuw 2013;104: 111-22.
2. Arendrup MC. Update on antifungal resistance in Aspergillus and Candida. Clin Microbiol Infect 2014;20(Suppl 6):42-8.
3. Arendrup MC, Dzajic E, Jensen RH, et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 2013;19:E343-53.
4. Arendrup MC, Perlin DS. Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis 2014;27: 484-92.
5. Bairwa G, Kaur R. A novel role for a glycosylphosphatidylinositolanchored aspartyl protease, CgYps1, in the regulation of pH homeostasis in Candida glabrata. Mol Microbiol 2011;79: 900-13.
6. Bairwa G, Rasheed M, Taigwal R, et al. GPI (glycosylphosphatidylinositol)- linked aspartyl proteases regulate vacuole homoeostasis in Candida glabrata. Biochem J 2014;458:323-34.
7. Ben-Ami R, Garcia-Effron G, Lewis RE, et al. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis 2011;204: 626-35.
8. Borah S, Shivarathri R, Srivastava VK, et al. Pivotal role for a tail subunit of the RNA polymerase II mediator complex CgMed2 in azole tolerance and adherence in Candida glabrata. Antimicrob Agents Ch 2014;58:5976-86.
9. Brunke S, Seider K, Heyken A, et al. Candida glabrata tryptophanbased pigment production via the Ehrlich pathway. Mol Microbiol 2010;76:25-47.
10. Casadevall A, Pirofski L. Host-pathogen interactions: the attributes of virulence. J Infect Dis 2001;184:337-44.
11. Chauhan N, Kruppa M, Calderone R. The Ssk1p response regulator and Chk1p histidine kinasemutants of Candida albicans are hypersensitive to fluconazole and voriconazole. Antimicrob Agents Ch 2007;51:3747-51.
12. Cormack BP, Ghori N, Falkow S. An adhesin of the yeast pathogen Candida glabrata mediating adherence to human epithelial cells. Science 1999;285:578-82.
13. Cowen LE, Kohn LM, Anderson JB. Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans. J Bact 2001;183:2971-8.
14. Cuellar-Cruz M, Briones-Martin-del-Campo M, Canas-Villamar I, et al. High resistance to oxidative stress in the fungal pathogen Candida glabrata is mediated by a single catalase, Cta1p, and is controlled by the transcription factors Yap1p, Skn7p, Msn2p, and Msn4p. Eukaryot Cell 2008;7:814-25.
15. de Groot PW, Bader O, de Boer AD, et al. Adhesins in human fungal pathogens: glue with plenty of stick. Eukaryot Cell 2013;12:470-81.
16. Domergue R, Castano I, De Las Penas A, et al. Nicotinic acid limitation regulates silencing of Candida adhesins during UTI. Science 2005;308:866-70.
17. Dujon B, Sherman D, Fischer G, et al. Genome evolution in yeasts. Nature 2004;430:35-44.
18. Edlind TD, Katiyar SK. Mutational analysis of flucytosine resistance in Candida glabrata. Antimicrob Agents Ch 2010;54: 4733-8.
19. Edwards JE, Jr. Invasive candida infections-evolution of a fungal pathogen. New Engl J Med 1991;324:1060-2.
20. Eggimann P, Pittet D. Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. Intens Care Med 2014;40:1429-48.
21. Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 2005;41:1559-68.
22. Ferrari S, Ischer F, Calabrese D, et al. Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but aso enhance virulence. PLoS Pathog 2009;5:e1000268.
23. Ferrari S, Sanguinetti M, De Bernardis F, et al. Loss of mitochondrial functions associated with azole resistance in Candida glabrata also results in enhanced virulence in mice. Antimicrob Agents Ch 2011a;55:1852-60.
24. Ferrari S, Sanguinetti M, Torelli R, et al. Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrata. PLoS One 2011b;6:e17589.
25. Fradin C, Mavor AL, Weindl G, et al. The early transcriptional response of human granulocytes to infection with Candida albicans is not essential for killing but reflects cellular communications. Infect Immun 2007;75:1493-501.
26. Gabaldón T, Martin T, Marcet-Houben M, et al. Comparative genomics of emerging pathogens in the Candida glabrata clade. BMC Genomics 2013;14:1-1.
27. Ghannoum MA, Jurevic RJ, Mukherjee PK, et al. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. PLoS Pathog 2010;6:e1000713.
28. Graybill JR, Montalbo E, Kirkpatrick WR, et al. Fluconazole versus Candida albicans: a complex relationship. Antimicrob Agents Ch 1998;42:2938-42.
29. Huang M, McClellan M, Berman J, et al. Evolutionary dynamics of Candida albicans during in vitro evolution. Eukaryot Cell 2011;10:1413-21.
30. Hull CM, Bader O, Parker JE, et al. Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2. Antimicrob Agents Ch 2012a;56:6417-21.
31. Hull CM, Parker JE, Bader O, et al. Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting crossresistance to azoles and amphotericin B. Antimicrob Agents Ch 2012b;56:4223-32.
32. Iraqui I, Garcia-Sanchez S, Aubert S, et al. The Yak1p kinase controls expression of adhesins and biofilm formation in Candida glabrata in a Sir4p-dependent pathway. Mol Microbiol 2005;55:1259-71.
33. Jacobsen ID, Brunke S, Seider K, et al. Candida glabrata persistence in mice does not depend on host immunosuppression and is unaffected by fungal amino acid auxotrophy. Infect Immun 2010;78:1066-77.
34. Jacobsen ID, Grosse K, Berndt A, et al. Pathogenesis of Candida albicans infections in the alternative chorio-allantoic membrane chicken embryomodel resembles systemicmurine infections. PLoS One 2011;6:e19741.
35. Kaur R, Domergue R, Zupancic ML, et al. A yeast by any other name: Candida glabrata and its interaction with the host. Curr Opin Microbiol 2005;8:378-84.
36. Kaur R, Ma B, Cormack BP. A family of glycosylphosphatidylinositol- linked aspartyl proteases is required for virulence of Candida glabrata. P Natl Acad Sci USA 2007; 104:7628-33.
37. Krogh-Madsen M, Arendrup MC, Heslet L, et al. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006;42: 938-44.
38. Kurtz M, Abruzzo G, Flattery A, et al. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immun 1996;64:3244-51.
39. Lau AF, Kabir M, Chen SC, et al. Candida colonization as a risk marker for invasive candidiasis in mixed medicalsurgical intensive care units: development and evaluation of a simple, standard protocol. J Clin Microbiol 2015;53: 1324-30.
40. Lee KK, Maccallum DM, Jacobsen MD, et al. Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob Agents Ch 2012;56:208-17.
41. Lewis RE, Viale P, Kontoyiannis DP. The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida. Virulence 2012;3:368-76.
42. Luque AG, Biasoli MS, Tosello ME, et al. Oral yeast carriage in HIVinfected and non-infected populations in Rosario, Argentina. Mycoses 2009;52:53-9.
43. Marichal P, Vanden Bossche H, Odds FC, et al. Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Ch 1997;41:2229-37.
44. Melnyk AH, Wong A, Kassen R. The fitness costs of antibiotic resistance mutations. Evol Appl 2014;8:273-83.
45. Muller H, Thierry A, Coppee JY, et al. Genomic polymorphism in the population of Candida glabrata: gene copy-number variation and chromosomal translocations. Fungal Genet Biol 2009;46:264-76.
46. Nagi M, Tanabe K, Ueno K, et al. The Candida glabrata sterol scavenging mechanism, mediated by the ATP-binding cassette transporter Aus1p, is regulated by iron limitation. Mol Microbiol 2013;88:371-81.
47. Orasch C, Marchetti O, Garbino J, et al. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland. Clin Microbiol Infect 2014;20:698-705.
48. Orsi CF, Colombari B, Ardizzoni A, et al. The ABC transporterencoding gene AFR1affects the resistance of Cryptococcus neoformans to microglia-mediated antifungal activity by delaying phagosomal maturation. FEMS Yeast Res 2009;9:301-10.
49. Orta-Zavalza E, Guerrero-Serrano G, Gutierrez-Escobedo G, et al. Local silencing controls the oxidative stress response and the multidrug resistance in Candida glabrata. Mol Microbiol 2013;88:1135-48.
50. Otto V, Howard DH. Further studies on the intracellular behavior of Torulopsis glabrata. Infect Immun 1976;14:433-8.
51. Paul S, Bair TB, Moye-Rowley WS. Identification of genomic binding sites for Candida glabrata Pdr1 transcription factor inwildtype and rho0 cells. Antimicrob Agents Ch 2014;58:6904-12.
52. Paul S, Schmidt JA, Moye-Rowley WS. Regulation of the CgPdr1 transcription factor from the pathogen Candida glabrata. Eukaryot Cell 2011;10:187-97.
53. Perez-Torrado R, Llopis S, Jespersen L, et al. Clinical Saccharomyces cerevisiae isolates cannot cross the epithelial barrier in vitro. Int J Food Microbiol 2012;157:59-64.
54. PfallerM, Diekema D. Epidemiology of invasivemycoses in North America. Crit Rev Microbiol 2010;36:1-53.
55. Pfaller M, Neofytos D, Diekema D, et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004-2008. Diagn Micr Infec Dis 2012a;74:323-31.
56. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012;125: S3-13.
57. Pfaller MA, Andes D, Diekema DJ, et al. Wild-type MIC distributions, epidemiological cutoffvalues and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Update 2010;13:180-95.
58. Pfaller MA, Castanheira M, Lockhart SR, et al. Frequency of decreased susceptibility and resistance to echinocandins 8 FEMS Yeast Research, 2015, Vol. 15, No. 4 among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012b;50:1199-203.
59. Pfaller MA, Castanheira M, Messer SA, et al. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp. Diagn Micr Infec Dis 2014;79:198-204.
60. Pham CD, Iqbal N, Bolden CB, et al. Role of FKS Mutations in Candida glabrata:MIC values, echinocandin resistance, andmultidrug resistance. Antimicrob Agents Ch 2014;58:4690-6.
61. Poĺaková S, Blume C, Źarate JA, et al. Formation of new chromosomes as a virulence mechanism in yeast Candida glabrata. P Natl Acad Sci USA 2009;106:2688-93.
62. Rai MN, Balusu S, Gorityala N, et al. Functional genomic analysis of Candida glabrata-macrophage interaction: role of chromatin remodeling in virulence. PLoS Pathog 2012;8:e1002863.
63. Rai MN, Sharma V, Balusu S, et al. An essential role for phosphatidylinositol 3-kinase in the inhibition of phagosomal maturation, intracellular survival and virulence in Candida glabrata. Cell Microbiol 2015;17:269-87.
64. Rodriguez-Tudela JL, Arendrup MC, Cuenca-Estrella M, et al. EUCAST breakpoints for antifungals. Drug News Perspect 2010;23:93.
65. Roetzer A, Gabaldon T, Schuller C. From Saccharomyces cerevisiae to Candida glabrata in a few easy steps: important adaptations for an opportunistic pathogen. FEMS Microbiol Lett 2011a;314:1-9.
66. Roetzer A, Gratz N, Kovarik P, et al. Autophagy supports Candida glabrata survival during phagocytosis. Cell Microbiol 2010;12:199-216.
67. Roetzer A, Klopf E, Gratz N, et al. Regulation of Candida glabrata oxidative stress resistance is adapted to host environment. FEBS Lett 2011b;585:319-27.
68. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002;2:73-85.
69. Sanguinetti M, Posteraro B, La Sorda M, et al. Role of AFR1, an ABC transporter-encoding gene, in the in vivo response to fluconazole and virulence of Cryptococcus neoformans. Infect Immun 2006;74:1352-9.
70. Seider K, Brunke S, Schild L, et al. The facultative intracellular pathogen Candida glabrata subverts macrophage cytokine production and phagolysosome maturation. J Immunol 2011;187:3072-86.
71. Selmecki AM, Dulmage K, Cowen LE, et al. Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. PLoS Genet 2009;5:e1000705.
72. Shin JH, Chae MJ, Song JW, et al. Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia. J Clin Microbiol 2007;45:2385-91.
73. Silva LV, Sanguinetti M, Vandeputte P, et al. Milbemycins: more than efflux inhibitors for fungal pathogens. Antimicrob Agents Ch 2013;57:873-86.
74. Singh-Babak SD, Babak T, Diezmann S, et al. Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. PLoS Pathog 2012;8:e1002718.
75. Sionov E, Lee H, Chang Y, et al. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog 2010;6: e1000848.
76. Slater JL, Howard SJ, Sharp A, et al. Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob Agents Ch 2011;55:3075-83.
77. Sobel JD, Fisher JF, Kauffman CA, et al. Candida urinary tract infections-epidemiology. Clin Infect Dis 2011;52:S433-6.
78. Song JW, Shin JH, Kee SJ, et al. Expression of CgCDR1, CgCDR2, and CgERG11 in Candida glabrata biofilms formed by bloodstream isolates. Med Mycol 2009;47:545-8.
79. Thakur JK, Arthanari H, Yang F, et al. A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature 2008;452:604-9.
80. Thierry A, Bouchier C, Dujon B, et al. Megasatellites: a peculiar class of giant minisatellites in genes involved in cell adhesion and pathogenicity in Candida glabrata. Nucleic Acids Res 2008;36:5970-82.
81. Thierry A, Dujon B, Richard GF. Megasatellites: a new class of large tandem repeats discovered in the pathogenic yeast Candida glabrata. Cell Mol Life Sci 2010;67:671-6.
82. Tsai H, Krol A, Sarti K, et al. Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants. Antimicrob Agents Ch 2006;50:1384-92.
83. Tsai H, Sammons L, Zhang X, et al. Microarray and molecular analyses of the azole resistance mechanism in Candida glabrata oropharyngeal isolates. Antimicrob Agents Ch 2010;54:3308-17.
84. Vale-Silva L, Ischer F, Leibundgut-Landmann S, et al. Gain-offunction mutations in PDR1, a regulator of antifungal drug resistance in Candida glabrata, control adherence to host cells. Infect Immun 2013;81:1709-20.
85. Vandeputte P, Tronchin G, Berges T, et al. Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth. Antimicrob Agents Ch 2007;51:982-90.
86. Vandeputte P, Tronchin G, Larcher G, et al. A nonsense mutation in the ERG6 gene leads to reduced susceptibility to polyenes in a clinical isolate of Candida glabrata. Antimicrob Agents Ch 2008;52:3701-9.
87. Walker LA, MacCallum DM, Bertram G, et al. Genome-wide analysis of Candida albicans gene expression patterns during infection of the mammalian kidney. Fungal Genet Biol 2009;46:210-9.
88. Westwater C, Schofield DA, Nicholas PJ, et al. Candida glabrata and Candida albicans; dissimilar tissue tropism and infectivity in a gnotobiotic model of mucosal candidiasis. FEMS Immunol Med Micr 2007;51:134-9.